Collagen type IV alpha 3 chain non-collagenous 1 domain (α3(IV)NC1)

The non-collagenous 1 (NC1) domain of the alpha 3 chain of type IV collagen, commonly known as α3(IV)NC1, is a specialized structural protein found primarily in the glomerular basement membrane (GBM) of the kidney and the alveolar basement membrane of the lungs (UniProt Q01955). It is clinically significant as the primary autoantigen in Goodpasture syndrome, also known as anti-GBM disease, where the immune system produces pathogenic autoantibodies against specific cryptic epitopes within this domain (Pedchenko et al., 2010, PubMed: 20107014). Under normal physiological conditions, these epitopes are sequestered within the NC1 hexamer structure, but their exposure can trigger a severe inflammatory cascade leading to rapidly progressive glomerulonephritis and pulmonary hemorrhage (Borza et al., 2005, PubMed: 15661978). Additionally, a 28-kDa fragment of this domain called tumstatin acts as an endogenous inhibitor of angiogenesis by binding to αVβ3 integrins, thereby inhibiting tumor growth (Maeshima et al., 2002, PubMed: 12050162). Mutations in the COL4A3 gene encoding this domain are also linked to Alport syndrome, a hereditary condition characterized by basement membrane thinning and progressive renal failure (Hudson et al., 2003, PubMed: 12788991). Current therapeutic interventions focus on the removal of anti-GBM antibodies via plasmapheresis or the suppression of antibody production using agents like rituximab and cyclophosphamide (StatPearls, 2023). Emerging treatments such as imlifidase aim to rapidly cleave the IgG antibodies targeting this domain to prevent irreversible organ damage.

Other names

Goodpasture antigenNC1 domain of COL4A3TumstatinNon-collagenous domain 1 of alpha 3 type IV collagenCOL4A3-NC1

Autoantibody binding to cryptic epitopes within the NC1 domain triggers complement activation and inflammatory cell recruitment, leading to basement membrane destruction in the kidneys and lungs.